0.17p
0.00%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About TheraCryf
Its shares trade on LSE under the ticker TCF.L. It has been listed since 21 October 2015. In the fiscal year to 31 March 2024, it reported revenue of £396,000 and a net loss of £3.1m. At that date it held total assets of £3.1m and shareholders' equity of £2.3m.
Evgen Pharma Plc is a clinical stage drug development company, which engages in the development of pharmaceutical products and focus on cancer and neurological disease. The company is headquartered in Wilmslow, Cheshire. The company went IPO on 2015-10-21. The firm operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. The company has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Oct 2015
- Employees
- 9
- Website
- evgen.com ↗
Leadership
Pay as last reported
- Dr. Alastair SmithNon-Executive Chairman of the Board
- Dr. Huw JonesChief Executive Officer, Executive Director, since 2020£204,190
- Mr. Toni HaenninenChief Financial Officer, Executive Director, since 2023£160,208
- Mr. Edward WardleNon-Executive Director
- Dr. Alan BargeNon-Executive Independent Director£14,742
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Evgen Pharma PLC possesses a robust intellectual property portfolio, which includes patents and trademarks. This provides a competitive advantage and enables the company to protect its innovative products and technologies in the pharmaceutical industry.
- The company has a highly skilled team of scientists and researchers dedicated to conducting advanced research and development activities. This expertise allows Evgen Pharma to continuously innovate and develop novel pharmaceutical products to meet market demands.
Weaknesses
- Evgen Pharma PLC currently relies on a limited product portfolio, which may limit its revenue potential and market opportunities. A more diversified product range could enhance the company's growth prospects and reduce dependency on specific products.
- The company's financial resources are relatively constrained, which may hinder its ability to invest in large-scale marketing, research, and infrastructure projects. A lack of financial flexibility could limit Evgen Pharma's expansion and competitiveness in the industry.
Opportunities
- The global pharmaceutical market is experiencing significant growth, driven by increasing healthcare needs, advancing technologies, and aging populations. Evgen Pharma can capitalize on this opportunity by expanding its presence in key markets, introducing new products, and adapting to evolving industry trends.
- Personalized medicine is gaining traction as it offers tailored treatment options based on individual patient characteristics. Evgen Pharma can leverage its expertise in drug development to align with this emerging trend, developing personalized therapies that target specific diseases and patient profiles.
Threats
- The pharmaceutical sector is highly competitive, with numerous established players and new entrants vying for market share. Evgen Pharma must continuously strive to differentiate itself through innovative products, strong marketing strategies, and effective pricing to withstand competition and maintain its position.
- Evgen Pharma operates in a heavily regulated industry subject to stringent regulatory requirements. Compliance with regulations, such as clinical trial regulations, drug approvals, and product labeling, is essential. Any failure to adhere to these regulations could lead to delays, additional costs, or even penalties, impacting the company's operations and reputation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.